It will be difficult to identify a sufficiently large sample size to improve risk estimates as the numbers of carriers of BARD1 variants are rare, as has been observed for carriers of potentially pathogenic PALB2, BRIP1, RAD51C or RAD51D variants in hereditary BC and/or OC cancer syndrome families (Figure 3) [145,146]. This evidence concerns the gene RAD51D and breast cancer.